{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:04:29Z","timestamp":1753869869817,"version":"3.41.2"},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:00:00Z","timestamp":1695513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe utilization patterns, characteristics of users and prescribers of the new oral antiviral medication, molnupiravir, indicated for mild\u2010to\u2010moderate COVID\u201019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using nationwide registries, we identified all Danish adults who filled a prescription for molnupiravir from December 16th, 2021, to August 31st, 2022. We described weekly incidence rates and patient characteristics over time, prescriber characteristics as well as time between molnupiravir initiation and a positive SARs\u2010CoV\u20102 test. Patient characteristics were compared to matched, untreated SARS\u2010CoV\u20102 positive reference groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By August 31st, 2022, 5847 individuals had filled a prescription for molnupiravir. The incidence rate gradually increased to 16 weekly prescriptions per 1000 RT\u2010PCR SARS\u2010CoV\u20102 positives. Users of molnupiravir were most often men (55% vs. 45% women). The majority (81%) had a positive RT\u2010PCR SARS\u2010CoV\u20102 test and few (2.9%) redeemed molnupiravir outside the recommended window of 5\u2009days from the positive test result. Compared to matched, untreated SARS\u2010CoV\u20102 positive reference groups, users of molnupiravir had a median age of 74\u2009years versus 49\u2009years, a higher proportion resided in a nursing home (12% vs. 1.5%) and had a higher number of comorbidities (median of 3 vs. 0); most commonly hypertension (38%), chronic lung disease (35%), diabetes (20%) and mood disorders (20%). General practitioners were the primary prescribers of molnupiravir (91%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Molnupiravir was mainly prescribed by general practitioners to RT\u2010PCR SARS\u2010CoV\u20102 positive individuals who had a potentially increased risk of severe COVID\u201019. Though some off\u2010label prescribing occurred, our study indicates a high level of adherence to contemporary guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5700","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T02:20:29Z","timestamp":1695608429000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of molnupiravir: A Danish nationwide drug utilization study"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5849-5358","authenticated-orcid":false,"given":"Louise","family":"Ladebo","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5962-6647","authenticated-orcid":false,"given":"Lotte","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5435-9092","authenticated-orcid":false,"given":"Peter Bj\u00f8dstrup","family":"Jensen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Lindahl","sequence":"additional","affiliation":[{"name":"L\u00e6gekompagniskabet Venusvej 2  Fredericia Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2594-6500","authenticated-orcid":false,"given":"Anne","family":"\u00d8vrehus","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Odense University Hospital, Clinical Research Unit University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-6594","authenticated-orcid":false,"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-4385","authenticated-orcid":false,"given":"Mette","family":"Reilev","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9,24]]},"reference":[{"volume-title":"EMA Issues Advice on Use of Lagevrio (Molnupiravir) for the Treatment of COVID\u201019","year":"2021","author":"European Medicines Agency","key":"e_1_2_10_2_1"},{"volume-title":"WHO Updates its Treatment Guidelines to Include Molnupiravir","year":"2022","author":"World Health Organization","key":"e_1_2_10_3_1"},{"key":"e_1_2_10_4_1","unstructured":"Decision.Summary of Product Characteristics for Lagevrio. Updated 20 December 2021. In: govuk.2021Accessed August 7 2022.https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-lagevrio-molnupiravir\/summary-of-product-characteristics-for-lagevrio#date-of-revision-of-the-text"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed\u20102022\u2010000276"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw213"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560\u20107917.es2014.19.1.20667"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810387965"},{"key":"e_1_2_10_10_1","unstructured":"Recently marketed drugs. Accessed September 16 2022.https:\/\/www.esundhed.dk\/Registre\/Laegemiddelstatistikregisteret\/Nye-leagemidler"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399956"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T10:51:41Z","timestamp":1706093501000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,24]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/pds.5700"],"URL":"https:\/\/doi.org\/10.1002\/pds.5700","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2023,9,24]]},"assertion":[{"value":"2023-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5700"}}